When Olaparib Stops Working: — Resistance and What Comes Next

This is generally not recommended once resistance to olaparib has been confirmed. The resistance mechanisms that develop — particularly reversion mutations — tend to affect the whole PARP inhibitor class rather than olaparib alone. NCCN and ESMO guidance advises against sequential use of PARP inhibitors in this setting. Your oncologist may still discuss it if your circumstances are unusual, but it is not the standard next step.

Not necessarily. Chemotherapy works through different mechanisms, and some patients whose cancers have become resistant to olaparib still respond to platinum-based drugs such as carboplatin. Whether you are likely to benefit depends partly on how sensitive your cancer was to platinum before olaparib, which is something your oncologist can assess from your treatment history. Resistance to olaparib and resistance to chemotherapy are separate questions.

Yes, though not always with a definitive result. Liquid biopsy — a blood test looking for circulating tumour DNA — can sometimes detect reversion mutations without a new tissue biopsy. Repeat tissue biopsy can give more detail if liquid biopsy is inconclusive. Knowing the mechanism matters because it can help narrow down which next-line treatments are more or less likely to work. Ask your oncologist whether resistance testing is appropriate in your case.

There is genuine variation, and the published evidence describes a wide range rather than a consistent timeline. Resistance is typically identified when scans show the cancer has begun to progress while you are on olaparib, which can happen after months or considerably longer. The timing reflects factors specific to your tumour biology, and a meaningful figure for your situation cannot be drawn from population averages. Your oncologist can tell you what the pattern has looked like in your own case.

For most patients, re-challenging with olaparib after confirmed resistance is not expected to work, because the resistance mechanisms do not reverse with a break. There are rare individual reports of re-challenge being considered in specific circumstances, but this is not standard practice and is not something to plan around. The more productive question is which of the available next-line options fits your situation, and your oncologist can address that directly.

Several trials are investigating treatments specifically for patients who have progressed on PARP inhibitors. These include combinations pairing a PARP inhibitor with agents targeting related DNA-damage pathways, antibody-drug conjugates, and newer targeted approaches. What is open depends on your cancer type, your BRCA status, and which treatments you have already had. Your oncologist or a second opinion at a centre with an active trials programme is the right place to ask — the answer changes as trials open and close.